DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain

Histochemistry and Cell Biology

Volumn 127, Issue 2, 2007, Pages 195-203

  Ye, Weizhen ^a   Mairet Coello, Georges ^a   DiCicco Bloom, Emanuel ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bromodeoxyuridine *immunology; Cyclin dependent kinase inhibitor p57Kip2 immunoreactivity; Immunohistochemistry technique; Neurogenesis embryonic rat brain; Nuclear proteins *analysis

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BROXURIDINE; CHLORIDE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DEOXYRIBONUCLEASE I; DNA; EPITOPE; ISOPROPAMIDE IODIDE; NUCLEAR FACTOR; PARAFORMALDEHYDE;

ANIMAL TISSUE; ARTICLE; BIOTINYLATION; BRAIN; CANCER DIAGNOSIS; CONTROLLED STUDY; DEGRADATION; DIAGNOSTIC ACCURACY; EMBRYO; FROZEN SECTION; IMMUNODETECTION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RELIABILITY;

ANIMALS; BRAIN; BRAIN CHEMISTRY; BROMODEOXYURIDINE; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DEOXYRIBONUCLEASE I; EMBRYO; FEMALE; IMMUNOHISTOCHEMISTRY; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 33846446479     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-006-0238-6     Document Type: Article

References (47)

1. Bhuiyan ZA, Yatsuki H, Sasaguri T, Joh K, Soejima H, Zhu X, Hatada I, Morisaki H, Morisaki T, Mukai T (1999) Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome. Hum Genet 104:205-210
2. Carey RG, Li B, DiCicco-Bloom E (2002) Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity. J Neurosci 22:1583-1591
3. Caspary T, Cleary MA, Perlman EJ, Zhang P, Elledge SJ, Tilghman SM (1999) Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev 13:3115-3124
4. Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW (2000) Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J Biol Chem 275:35942-35952
5. Dyer MA, Cepko CL (2000) p57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development 127:3593-3605
6. Dyer MA, Cepko CL (2001) p27Kip1 and p57Kip2 regulate proliferation in distinct retinal progenitor cell populations. J Neurosci 21:4259-4271
7. Erber WN, Willis JI, Hoffman GJ (1997) An enhanced immunocytochemical method for staining bone marrow trephine sections. J Clin Pathol 50:389-393
8. van Gijssel HE, van Gijlswijk RP, de Haas RR, Stark C, Mulder GJ, Meerman JH (1998) Immunohistochemical visualization of wild-type p53 protein in paraffin-embedded rat liver using tyramide amplification: zonal hepatic distribution of p53 protein after N-hydroxy-2-acetylaminofluorene administration. Carcinogenesis 19:219-222
9. Gonchoroff NJ, Katzmann JA, Currie RM, Evans EL, Houck DW, Kline BC, Greipp PR, Loken MR (1986) S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. J Immunol Methods 93:97-101
10. de Haas RR, Verwoerd NP, van der Corput MP, van Gijlswijk RP, Siitari H, Tanke HJ (1996) The use of peroxidase-mediated deposition of biotin-tyramide in combination with time-resolved fluorescence imaging of europium chelate label in immunohistochemistry and in situ hybridization. J Histochem Cytochem 44:1091-1099
11. Hatada I, Mukai T (1995) Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11:204-206
12. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, Yutani C, Takahashi S, Chiba Y, Ohishi S, Mukai T (1996a) Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 5:783-788
13. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Nakayama M, Niikawa N, Mukai T (1996b) An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 14:171-173
14. Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H, Niikawa N, Inoue M, Komoto Y, Okada A, Steichen E, Ohashi H, Fukushima Y, Nakayama M, Mukai T (1997) New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum Genet 100:681-683
15. Hiort O, Kwan PW, DeLellis RA (1988) Immunohistochemistry of estrogen receptor protein in paraffin sections. Effects of enzymatic pretreatment and cobalt chloride intensification. Am J Clin Pathol 90:559-563
16. Hiromura K, Haseley LA, Zhang P, Monkawa T, Durvasula R, Petermann AT, Alpers CE, Mundel P, Shankland SJ (2001) Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 60:2235-2246
17. Hume WJ, Keat S (1990) Immunohistological optimization of detection of bromodeoxyuridine-labeled cells in decalcified tissue. J Histochem Cytochem 38:509-513
18. Hunyady B, Krempels K, Harta G, Mezey E (1996) Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem 44:1353-1362
19. Jun SY, Ro JY, Kim KR (2003) p57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathology 43:17-25
20. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P (2000) Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 31:751-760
21. Kressel M (1998) Tyramide amplification allows anterograde tracing by horseradish peroxidase-conjugated lectins in conjunction with simultaneous immunohistochemistry. J Histochem Cytochem 46:527-533
22. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
23. Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, Donnai D, Reik W, Schofield PN, Maher ER (1999) Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet 36:518-523
24. Lee MH, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649
25. Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, Mori N, Saito H, Kinoshita T (2002) Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 100:2572-2577
26. Li JQ, Wu F, Usuki H, Kubo A, Masaki T, Fujita J, Bandoh S, Saoo K, Takeuchi H, Kuriyama S, Ishida T, Imaida K (2003) Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 23:1537-1543
27. Li G, Domenico J, Lucas JJ, Gelfand EW (2004) Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes. J Immunol 173:2383-2391
28. Matsumoto M, Furihata M, Ohtsuki Y, Sasaguri S, Ogoshi S (2000) Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res 20:1947-1952
29. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662
30. Nagahama H, Hatakeyama S, Nakayama K, Nagata M, Tomita K (2001) Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p57Kip2 during mouse development. Anat Embryol (Berl) 203:77-87
31. Nakai S, Masaki T, Shiratori Y, Ohgi T, Morishita A, Kurokohchi K, Watanabe S, Kuriyama S (2002) Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 20:769-775
32. Plenat F, Picard E, Antunes L, Vignaud JM, Marie B, Chalabreysse P, Muhale F (1997) Amplification of immunologic reactions using catalytic deposition at the reaction sites of tyramine derivatives. A decisive gain in sensitivity in immunohistochemistry and in situ hybridization. Ann Pathol 17:17-23
33. Reynaud EG, Pelpel K, Guillier M, Leibovitch MP, Leibovitch SA (1999) p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. Mol Cell Biol 19:7621-7629
34. Said JW, Shintaku IP, Pinkus GS (1988) Immunohistochemical staining for terminal deoxynucleotidyl transferase (TDT). An enhanced method in routinely processed formalin-fixed tissue sections. Am J Clin Pathol 89:649-652
35. Sasaki K, Adachi S, Yamamoto T, Murakami T, Tanaka K, Takahashi M (1988) Effects of denaturation with HCl on the immunological staining of bromodeoxyuridine incorporated into DNA. Cytometry 9:93-96
36. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M (2005) Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 11:4681-4688
37. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G (2003) Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101:4131-4136
38. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512
39. Shintaku IP, Said JW (1987) Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Use of DNase pretreatment to enhance sensitivity of the reaction. Am J Clin Pathol 87:161-167
40. Suh J, Carey R, DiCicco-Bloom E (2001) PACAP negatively regulates precursor proliferation through p57kip2 inhibition of cdk2 in developing cerebral cortex. Soc Neurosci 27:Abstract # 896.816
41. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M (2002) Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 22:3191-3196
42. Williamson K, Gilliland R, Weir H, Grimes J, Hamilton P, Anderson N, Crockard A, Rowlands B (1994) Hydrochloric acid denaturation of colorectal tumour tissue infiltrated with bromodeoxyuridine. Cytometry 15:162-168
43. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M (1997) Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 11:973-983
44. Ye W, DiCicco-Bloom E (2005) Localization of cdk inhibitor p57kip2 between zones of proliferation and differentiation in the embryonic brain suggests roles in cell-cycle exit and differentiation. Program No. 598.16. 2005 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington (Online)
45. Yue H, Jiang HY (2005) Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study. World J Gastroenterol 11:5057-5060
46. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ (1997) Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158
47. Zhang P, Wong C, Liu D, Finegold M, Harper JW, Elledge SJ (1999) p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev 13:213-224